Moxifloxacina Teva

Moxifloxacin, the active ingredient in Moxifloxacina Teva, is a fluoroquinolone presented as an oral tablet for systemic use. It treats a range of serious bacterial infections in adults, including community‑acquired pneumonia, acute bacterial sinusitis, acute exacerbations of chronic bronchitis, skin and soft‑tissue infections, and intra‑abdominal infections.

GNH USA supplies Moxifloxacina Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin is indicated for several bacterial infections affecting the respiratory, skin and intra‑abdominal systems. - Community‑acquired bacterial pneumonia: achieves bacterial eradication and clinical cure in adult patients. - Acute bacterial sinusitis: reduces symptoms and eliminates the causative pathogens. - Acute bacterial exacerbation of chronic bronchitis: improves lung function and shortens disease duration. - Skin and soft‑tissue infections: provides effective bacterial clearance. - Intra‑abdominal infections: supports resolution of infection in the abdominal cavity.

Moxifloxacin may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Abdominal pain - Rash

Serious or Rare Side Effects: - Tendon rupture or tendinitis - QT interval prolongation and arrhythmias - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Clostridioides difficile‑associated colitis - Hepatic toxicity - Peripheral neuropathy

When prescribing moxifloxacin, clinicians should consider several precautionary measures to minimise risk. - Renal function assessment: evaluate kidney function and adjust use in severe impairment. - Tendon health monitoring: discontinue if tendon pain, swelling, or inflammation occurs. - QT interval evaluation: avoid in patients with known QT prolongation or concurrent QT‑prolonging drugs. - Concurrent NSAID use: increased risk of tendon rupture; use with caution. - Elderly patients: higher incidence of adverse events; monitor closely. - Store at below 25°C: keep in the original pack, protect from moisture.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other fluoroquinolones: additive toxicity, avoid co‑administration. - QT‑prolonging agents (e.g., quinidine, macrolides): risk of serious arrhythmia. - Antacids or supplements containing magnesium, aluminum, calcium, or iron: markedly reduce absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation parameters. - Corticosteroids: increased risk of tendon rupture; observe for symptoms.